Advanced glycation end products and diabetic retinopathy

Amino Acids

Volumn 44, Issue 6, 2013, Pages 1397-1407

  Milne, Ross ^a   Brownstein, Seymour ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Advanced glycation endproducts; Diabetic complications; Dicarbonyls; Endothelial cells; Methylglyoxal; Pericytes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALDEHYDE DERIVATIVE; ALPHA OXOALDEHYDE; AMINE; BENFOTIAMINE; DICARBONYL DERIVATIVE; HYDROXYACYLGLUTATHIONE HYDROLASE; KETONE; LACTOYLGLUTATHIONE LYASE; METHYLGLYOXAL; MITOCHONDRIAL PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLIGONUCLEOTIDE APTAMER; PEPTIDE APTAMER; PF 4494700; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

BLINDNESS; BLOOD RETINA BARRIER; CELL ADHESION; CELL LOSS; CLINICAL TRIAL (TOPIC); DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MICROANEURYSM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PERICYTE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; RECEPTOR BINDING; RETINA CAPILLARY; RETINA NEOVASCULARIZATION; REVIEW; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT;

ANIMALS; BLOOD-RETINAL BARRIER; DIABETIC RETINOPATHY; GLYCOSYLATION END PRODUCTS, ADVANCED; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PYRIDOXAMINE; PYRUVALDEHYDE; RETINA; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 84878226453     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-1071-3     Document Type: Review

References (155)

1. Abordo EA, Minhas HS, Thornalley PJ (1999) Accumulation of a-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochem Pharmacol 58:641-648
2. Ahmed N, Thornalley PJ (2007) Advanced glycation endproducts: what is their relevance to diabetic complications. Diabetes Obes Metab 9:233-245
3. Ahmed N, Thornalley PJ, Dawczynski J, Franke S, Strobel J, Stein G, Haik GM (2003) Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. Invest Ophthalmol Vis Sci 44:5287-5292
4. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL3, Klein R (1998) Diabetic retinopathy. Diabetes Care 21:143-156
5. Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleestra N, Slingerland RJ, Mijnhout GS, Bilo HJG, Gans ROB, Navis GJ, Barker SJL (2010) A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33:1598-1601
6. Allt G, Lawrenson JG (2001) Pericytes: cell biology and pathology. Cells Tissues Organs 169:1-11
7. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA (1989) An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86:4544-4548
8. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW (1998) Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 47:1953-1959
9. Armulik A, Abramsson A, Betsholtz C (2005) Endothelial/pericyte interactions. Circ Res 97:512-523
10. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabtic nepthropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110-2120
11. Barile GR, Pachydaki S, Tan SR, Lee SE, Donmoyer CM, Ma W, Rong LL, Buciarelli LG, Wendt T, Horig H, Hudson BI, Qu W, Weinberg AD, Yan SF, Schmidt AM (2005) The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 46:2916-2924
12. Barile GR, Schmidt AM (2007) RAGE and its ligands in retinal disease. Curr Mol Med 7:758-765
13. Beltramo E, Pomero F, Allione A, D'Alu F, Ponte E, Porta M (2002) Pericyte adhesion is impaired on extracellular matrix produced by endothelial cells in high hexose concentrations. Diabetologia 45:416-419
14. Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591-1598
15. Bergers G, Song S (2005) The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 7:452-464
16. Bhatwadekar AD, Glenn JV, Figarola JL, Scott S, Gardiner TA, Rahbar S, Stitt AW (2008a) A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol 92:545-547
17. Bhatwadekar AD, Glenn JV, Li G, Curtis TM, Gardiner TA, Stitt AW (2008b) Advanced glyation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. Invest Ophthalmol Vis Sci 49:1232-1241
18. Bidasee KR, Nallani K, Yu YQ, Cocklin RR, Zhang YN, Wang M, Dincer ÜD, Besch HR Jr (2003) Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium release channels. Diabetes 52:1825-1836
19. 2+-ATPase. Diabetes 53:463-473
20. Boehm BO, Lang G, Volpert O, Jehle PM, Kurkhaus A, Rosinger S, Lang GK, Bouck N (2003) Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologia 46:394-400
21. Bolton SJ, Anthony DC, Perry VH (1998) Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience 86:1245-1257
22. Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov SN, Osborne NN, Reichenbach A (2006) Müller cells in the healthy and diseased retina. Prog Retin Eye Res 25:397-424
23. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
24. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625
25. Brunner S, Schernthaner GH, Satler M, Elhenicky M, Hoellerl F, Schmid-Kubista KE, Zeiler F, Binder S, Schernthaner G (2009) Correlation of different circulating endothelial progenitor cells to stages of diabetic retinopathy-first in vivo data. Invest Ophthalmol Vis Sci 9:392-398
26. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap YK, Stern DM, Schmidt AM (2002a) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827-2835
27. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, Schmidt AM (2002b) RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59:1117-1128
28. Busik JV, Mohr S, Grant MB (2008) Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes 57:1952-1965
29. Busik JV, Olson K, Grant MB, Henry DN (2002) Glucose-induced activation of glucose uptake in cells from the inner and outer blood-retinal barrier. Invest Ophthalmol Vis Sci 43:2356-2363
30. Caballero S, Sengupta N, Afzal A, Chang KH, Calzi SL, Guberski DL, Kern TS, Grant MB (2007) Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes 56:960-967
31. Cai J, Kehoe O, Smith GM, Hykin P, Boulton ME (2008) The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci 49:2163-2171
32. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Caldwell RW (2003) Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 19:442-455
33. Cameron AD, Olin B, Ridderstrøm M, Mannervik B, Jones TA (1997) Crystal structure of human glyoxalase I - evidence for gene duplication and 3D domain swapping. EMBO J 16:3386-3395
34. Cameron AD, Ridderstrøm M, Olin B, Kavarana MJ, Creighton DJ, Mannervik B (1999) Reaction mechanism of glyoxalase I explored by an X-ray crystallographic analysis of the human enzyme in complex with a transition state analogue. Biochemistry 38:13480-13490
35. Chavakis T, Bierhaus A, Al-Fakhri N, Achneider D, Witte S, Linn T, Bagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP (2003) The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198:1507-1515
36. Chibber R, Molinatti PA, Kohner EM (1999) Intracellular protein glycation in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration. Cell Mol Biol 45:47-57
37. Chibber R, Molinatti PA, Rosatto N, Lambourne B, Kohner EM (2004) Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia 40:156-164
38. Cordell PA, Futers TS, Grant PJ, Pease RJ (2004) The human hydroxyacylglutathione hydrolase (HAGH) gene encodes both cytoplasmic and mitochondrial forms of glyoxalase II. J Biol Chem 279:28653-28661
39. Cunha-Vaz J, Faria de Abreu JR, Campos AJ (1975) Early breakdown of the blood-retinal barrier in diabetes. Brit J Opthalmol 59:649-656
40. Curtis TM, Hamilton R, Yong PH, McVicar CM, Berner A, Pingle R, Uchida K, Nagai R, Brockbank S, Stitt AW (2011) Müller glial dysfunction during diabetic retinopathy in rats is linked to the accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia 54:690-698
41. Darland DC, Massingham LJ, Smith SR, Piek E, Saint-Geniez M, D'Amore PA (2004) Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 264:275-288
42. De La Cruz JP, Gonzalez-Correa JA, Guerrero A, de la Ceusta FS (2004) Pharmacological approach to diabetic retinopathy. Diabetes Metab Res Rev 20:91-113
43. Deane R, Yan SD, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-b peptide transport across the blood-brain barrier and accumulation in brain. Nature Med 9:907-913
44. Del Maschio A, Zanetti A, Corada M, Rival Y, Ruco L, Lampugnani MG, Dejana E (1996) Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol 135:497-510
45. Deng YL, Yu PH (2004) Assessment of the deamination of aminoacetone, an endogenous substrate for semicarbazide-sensitive amine oxidase. Anal Biochem 270:97-102
46. Du J, Zeng J, Ou X, Ren X, Cai S (2007) Methylglyoxal downregulates Raf-1 protein through a ubiquitination-mediated mechanism. Int J Biochem Cell Biol 38:1084-1091
47. Du X, Edelstein D, Brownlee M (2008) Oral benfotiamine plus a-lipoic acid normalizes complication-causing pathways in type 1 diabetes. Diabetologia 51:1930-1932
48. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengellér Z, Szabó C, Brownlee M (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049-1057
49. Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW (2008) Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab 10:53-63
50. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M (2008) Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205:2409-2417
51. Enge M, Bjarnegard M, Gerhardt H, Gustafsson E, Kalen M, Asker N, Hammes HP, Shani M, Fassler R, Betsholtz C (2002) Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J 21:4307-4316
52. Feng Y, Vom Hagen F, Pfisterer F, Djokic S, Hoffmann S, Back W, Wagner P, Deutsch LJ, Hammes HP (2007) Impaired recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost 97:99-108
53. Fosmark DS, Torjesen PA, Kilhovd BK, Berg TJ, Sandvik L, Hanssen KF, Agardh CD, Agardh E (2006) Increased serum levels of the specific advanced glycation end product methylglyoxal-derived hydroimidazolone are associated with retinopathy in patients with type 2 diabetes mellitus. Metabolism 55:232-236
54. Frank RN (2004) Diabetic retinopathy. N Engl J Med 350:48-58
55. Frank RN, Dutta S, Mancini MA (1987) Pericyte coverage is greater in the retinal than in the cerebral capillaries of the rat. Invest Ophthalmol Vis Sci 28:1086-1091
56. Frank RN, Turczyn TJ, Das A (1990) Pericyte coverage of retinal and cerebral capillaries. Invest Ophthalmol Vis Sci 31:999-1007
57. e-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982-9986
58. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM (2005) Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54:3103-3111
59. Goh SY, Cooper ME (2008) The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93:1143-1152
60. Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, Brownlee M, Schleicher ED (1999) Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 42:728-736
61. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Med 9:294-299
62. Hammes HP, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U (2004a) Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51:3107-3112
63. Hammes HP, Lin J, Wagner P, Feng Y, Vom Hagen F, Krzizok T, Renner O, Breier G, Brownlee M, Deutsch U (2004b) Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 53:1104-1110
64. Hammes HP, Feng Y, Pfister F, Brownlee M (2011) Diabetic retinopathy: targeting vasoregression. Diabetes 60:9-16
65. Hanahan D (1997) Signaling vascular morphogenesis and maintenance. Science 277:48-50
66. Heizmann CW (2007) The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: arguing against the motion. Molec Nut Food Res 51:1116-1119
67. Hellström I, Gerhardt H, Kalén M, Li X, Eriksson U, Wolburg H, Betsholtz C (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 153:543-553
68. Hellström I, Kalen M, Lindahl P, Abramsson A, Betsholtz C (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126:3047-3055
69. Hirschi KK, Rohovsky SA, D'Amore PA (1998) PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141:805-814
70. Hofmann MA, Drury S, Fu CF, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901
71. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, Morser J, Stern D, Schmidt AM (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270:25752-25761
72. Hudson BI, Bucciarelli LG, Wendt T, Sakaguchi T, Lalla E, Qu W, Lu Y, Lee L, Stern DM, Naka Y, Ramsamy R, Yan S-D, Yan SF, D'Agati V, Schmidt AM (2003) Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. Arch Biochem Biophys 419:80-88
73. Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JEB (2006) Diabetes and advanced glycoxidation end products. Diabetes Care 29:1420-1432
74. Januszewski AS, Alderson NL, Thorpe SR, Baynes JW (2003) Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem Soc Trans 31:1413-1416
75. Joussen AM (2001) Vascular plasticity-the role of the angiopoietins in modulating ocular angiogenesis. Graefes Arch Clin Exp Ophthalmol 239:972-975
76. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450-1452
77. Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, Ju ST, Rook SL, Esser P, Mitsiades CS, Kirchhof B, Adamis AP, Aiello LP (2003) Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J 17:76-78
78. Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, Moromizato Y, Bursell SE, Wiegand SJ, Rudge J, Ioffe E, Yancopoulos GD, Adamis AP (2002) Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 160:1683-1693
79. Kaji Y, Usui T, Ishida S, Moore TCB, Moore J, Yamamoto Y, Yamamoto H, Adamis AP (2007) Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 48:858-865
80. Kanwar M, Kowluru RA (2009) Role of glyceraldehyde 3-phosphate dehydrogenase in the the development and progression of diabetic retinopathy. Diabetes 58:227-234
81. Kim NS, Umezawa Y, Ohmura S, Kato S (1993) Human glyoxalase I. cDNA cloning, expression, and sequence similarity to glyoxalase I from Pseudomonas putida. J Biol Chem 268:11217-11221
82. Li YH, Lu WY, Schwartz AL, Bu GJ (2002) Receptor-associated protein facilitates proper folding and maturation of the low-density lipoprotein receptor and its class 2 mutants. Biochemistry 41:4921-4928
83. Lindahl P, Johansson BR, Leveen P, Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-245
84. Liu B, Bhat M, Padival AK, Smith DG, Nagaraj RH (2004a) Effect of dicarbonyl modification of fibronectin on retinal capillary pericytes. Invest Ophthalmol Vis Sci 45:1983-1995
85. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY (2004b) Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 101:6605-6610
86. Liu M, Li Y, Cavener D, Arvan P (2005) Proinsulin disulfide maturation and misfolding in the endoplasmic reticulum. J Biol Chem 280:13209-13212
87. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP (1998) Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101:1219-1224
88. Mamputu JC, Renier G (2004) Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J Leukoc Biol 75:1062-1069
89. Mamputu JC, Renier G (2002) Advanced glycation end products increase, through a protein kinase C-dependent pathway, vascular endothelial growth factor expression in retinal endothelial cells. Inhibitory effect of gliclazide. J Diabetes Complications 16:284-293
90. McLellan AC, Thornalley PJ, Benn J, Sonksen PH (1993) Population genetics of human glyoxalases and the development of diabetic complications. Biochem Soc Trans 21:172S
91. McLellan AC, Thornalley PJ, Benn J, Sonkson PH (1994) Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 87:21-29
92. McLeod DS, Lefer DJ, Merges C, Lutty GA (1995) Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 147:642-653
93. Miller AG, Smith DG, Bhat M, Nagaraj RH (2006) Glyoxalase I Is critical for human retinal capillary pericyte survival under hyperglycemic conditions. J Biol Chem 281:11864-11871
94. Miller AG, Tan G, Binger KJ, Pickering RJ, Thomas MC, Nagaraj RH, Cooper ME, Wilkinson-Berka JL (2010) Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 59:3208-3215
95. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, Adamis AP (2000) Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 156:1733-1739
96. Miyata T, de Strihou C, Imasawa T, Yoshino A, Ueda Y, Ogura H, Kominami K, Onogi H, Inagi R, Nangaku M, Kurokawa K (2001) Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int 60:2351-2359
97. Mizutani M, Kern TS, Lorenzi M (2004) Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 97:2883-2890
98. Mohamed Q, Wong TY (2008) Emerging drugs for diabetic retinopathy. Exp Opin Emerg Drugs 13:675-694
99. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S (1999) Skin collagen glycaion, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes. Diabetes 48:870-880
100. Moore TCB, Moore JE, Kaji Y, Frizzell N, Usui T, Poulaki V, Campbell IL, Stitt AW, Gardiner TA, Archer DB, Pathog APPA (2003) The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci 44:4457-4464
101. Nambu H, Nambu R, Oshima Y, Hackett SF, Okoye G, Wiegand S, Yancopoulos G, Zack DJ, Ampochiaro PA (2004) Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Therapy 11:865-873
102. Navaratna D, McGuire PG, Menicucci G, Das A (2007) Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 56:2380-2387
103. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oats PJ, Hammes HP, Giardino I, Brownlee M (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790
104. Nishikiori N, Osanai M, Chiba H, Kojima T, Mitamura Y, Ohguro H, Sawada N (2007) Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retionpathy. Diabetes 56:1333-1340
105. Ohashi H, Takagi H, Koyama S, Oh H, Watanabe D, Antonetti DA, Matsubara T, Nagai K, Arai H, Kita T, Honda Y (2004) Alterations in expression of angiopoietins and the Tie-2 receptor in the retina of streptozotocin induced diabetic rats. Mol Vis 26:608-617
106. Otero K, Martínez F, Beltrán A, González D, Herrera B, Quintero G, Delgado R, Rojas A (2001) Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells. Biochem J 359:567-574
107. Peters S, Cree IA, Alexander R, Turowski P, Ockrim A, Patel J, Boyd SR, Joussen AM, Ziemssen F, Hykin PG, Moss SE (2007) Angiopoietin modulation of vascular endothelial growth factor: effects on retinal endothelial cell permeability. Cytokine 40:144-150
108. Pfister F, Feng Y, Vom Hagen F, Hoffmann S, Molema G, Hillebrands JL, Shani M, Deutsch U, Hammes HP (2008) Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy. Diabetes 57:2495-2502
109. Phillips SA, Mirrlees D, Thornalley PJ (1993) Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. Biochem Pharmacol 46:805-811
110. Podestà F, Romeo G, Liu WH, Krajewski S, Reed JC, Gerhardinger C, Lorenzi M (2000) Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. Am J Pathol 156:1025-1032
111. Rabbani N, Thornalley PJ (2008) The dicarbonyl proteome. Proteins susceptible to dicarbonyl glycation at functional sites in health, aging and disease. Ann NY Acad Sci 1126:124-127
112. Ramasamy R, Yan SF, Schmidt AM (2007) Arguing for the motion: Yes, RAGE is a receptor for advanced glycation endproducts. Moc Nutr Food Res 51:1111-1115
113. Ranganathan S, Ciaccio PJ, Walsh ES, Tew KD (1999) Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene 240:149-155
114. Ranganathan S, Walseh ES, Godwin AK, Tew KD (1993) Cloning and characterization of human colon glyoxalase-I. J Biol Chem 268:5661-5667
115. Ratliff DM, Vander Jagt DJ, Eaton RP, Vander Jagt DL (1996) Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II - a clinical research center study. J Clin Endocrinol Metab 81:488-492
116. Robison WG Jr, Tillis TN, Laver N, Kinoshita JH (1990) Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp Eye Res 50:355-366
117. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M (2002) Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51:2241-2248
118. Saaddine JB, Honeycutt AA, Narayan KMV, Zhang X, Klein R, Boyle JP (2008) Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus. Arch Opthalmol 126:1740-1747
119. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Tsuruo T (2000) Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 95:3214-3218
120. Sato Y, Rifkin DB (1989) Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 109:315
121. Schönfelder U, Hofer A, Paul M, Funk RHW (1998) In situ observation of living pericytes in rat retinal capillaries. Microvasc Res 56:22-29
122. Sebekova K, Somoza V (2007) Dietary advanced glycation endproducts (AGEs) and their health effects. Mol Nutr Food Res 51:1079-1084
123. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M (1998) Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 101:1142-1147
124. Sima J, Zhang SX, Shao C, Fant J, Ma JX (2004) The effect of angiostatin on vascular leakage and VEGF expression in rat retina. FEBS Lett 564:19-23
125. Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetologia 44:129-146
126. Stitt A, Gardiner TA, Anderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51:2826-2832
127. Stitt AW (2003) The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 75:95-108
128. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB (2004a) Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun 3:380-388
129. Stitt AW, Hughes SJ, Canning P, Lynch O, Cox O, Frizzell N, Thorpe SR, Cotter TG, Curtis TM, Gardiner TA (2004b) Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. Diabetologia 47:1735-1746
130. Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H (1997) Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 150:523-531
131. Sundberg C, Kowanetz M, Brown LF, Detmar M, Dvorak HF (2004) Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 82:387-401
132. Takeuchi M, Takino JI, Yamagishi SI (2010) Involvement of TAGE-RAGE system in the pathogenesis of diabetic retinopathy. J Ophthalmol 2010:170393
133. Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, Galiano RD, Du XL, Grogan R, Galvez MG, Januszyk M, Brownlee M, Gurtner GC (2009) The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA 106:13505-13510
134. The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559
135. The Advance Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572
136. Thornalley PJ (1993) The glyoxalase system in health and disease. Molec Aspects Med 14:287-371
137. Thornalley PJ (1998) Glutathione-dependent detoxification of a-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 111-112:137-151
138. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375:581-592
139. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E (2001) Regulation of vascular endothelial growth factor expression by advanced glycation end products. J Biol Chem 276:43836-43841
140. Tretoacj M, Madigan MC, Wen L, Gillies MC (2008) Effect of Müller cell co-culture on in vitro permeability of bovine retinal vascular endothelium in normoxic and hypoxic conditions. Neurosci Lett 378:160-165
141. Ulrich P, Cerami A (2001) Protein glycation, diabetes and aging. Recent Prog Horm Res 56:1-21
142. United Kingdom Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
143. Vasan S, Foiles P, Founds H (2003) Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 419:89-96
144. Vincent JA, Mohr S (2007) Inhibition of caspase-1/interleukin-1b signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 56:224-230
145. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 99:15596-15601
146. Warboys CM, Toh HB, Fraser PA (2009) Advanced glycation end products rapidly increase retinal microvascular permeability via RAGE activation of NADPH oxidase. Invest Ophthalmol Vis Sci 50:1319-1328
147. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI (1998) Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 95:4630-4634
148. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Koga K, Sasaki N, Yamamoto H, Takeuchi M, Makita Z (2002) Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 290:973-978
149. Yamagishi S, Hsu CC, Taniguchi M, Harada S, Yamamoto Y, Ohsawa K, Kobayashi K, Yamamoto H (2004) Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy. Biochem Biophys Res Commun 213:681-687
150. Yamagishi S, Ueda S, Okuda S (2007) Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 13:2832-2836
151. Yan SF, Ramasamy R, Naka Y, Schmidt AM (2003) Glycation, inflammation, and RAGE. A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93:1159-1169
152. Yan S-D, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691
153. Yao D, Brownlee M (2009) Hyperglycemia-induced reactive oxygen species increase expression of RAGE and RAGE ligands. Diabetes 59:249-255
154. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, Suske G, Ahmed N, Thornalley PJ, Sarthy VP, Hammes HP, Brownlee M (2007) High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 282:31038-31045
155. Zheng L, Szabó C, Kern TS (2004) Poly(ADP-Ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-{kappa}B. Diabetes 53:2960-2967